爱尔眼科医院集团股份有限公司 2025 年第三次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第三次临时股 东大会采用现场表决与网络投票相结合的方式召开。其中通过深圳证券交易所交 易系统进行网络投票的时间为：2025年11月27日上午9:15至9:25、9:30至11:30， 下午 1:00 至 3:00；通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 27 日上午 9:15 至下午 3:00 期间的任意时间；现场会议于 2025 年 11 月 27 日下午 2:30 在长沙市芙蓉南路一段 188 号爱尔大厦北塔 8 楼闻道厅会议室召 开。本次股东大会由公司董事会召集，董事长陈邦先生主持，公司董事、高级管 理人员、律师等相关人士出席了本次会议。会议的召集、召开与表决程序符合法 律、行政法规、部门规章、规范性文件和《公司章程》的规定 ...

二零二五年十一月二十七日 致：爱尔眼科医院集团股份有限公司 湖南启元律师事务所（以下简称"本所"）接受爱尔眼科医院集团股份有限 公司（以下简称"公司"）的委托，指派本所律师出席了公司 2025 年第三次临时 股东大会（以下简称"本次股东大会"），对本次股东大会的召集和召开程序、 出席会议人员及召集人的资格、表决程序和表决结果的合法有效性进行律师见证， 并发表本法律意见。 湖南启元律师事务所 关于爱尔眼科医院集团股份有限公司 2025年第三次临时股东大会的 法律意见书 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《爱 尔眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定 出具本法律意见书。 为出具本法律意见书，本所律师声明如下： 2、出席会议的股东或其代理人的身份证明文件、授权委托书等； 3、本次股东大会股权登记日的公司股东名册、出席现场会议的股东的签到册 及相关资料； 4、网络投票的统计结果； 5、本次股东大会会议决议、表决资料等 ...

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-097 爱尔眼科医院集团股份有限公司 第七届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）2025 年第三次临时股 东大会于 2025 年 11 月 27 日召开，审议通过了公司董事会换届选举事宜，具体 内容详见同日披露的《2025 年第三次临时股东大会决议公告》。公司董事会已完 成换届选举，经全体董事一致同意，公司第七届董事会第一次会议于 2025 年 11 月 27 日在公司会议室以现场和通讯表决相结合的方式召开。会议由董事长陈邦 先生召集主持，应到董事 7 人，实到董事 7 人，会议的召开符合《公司法》和《公 司章程》的有关规定，会议合法、有效。经审议，本次会议一致通过如下议案： 一、《关于选举董事长、副董事长的议案》 根据《公司法》《公司章程》及其他有关规定，经董事会认真审议，选举陈 邦先生为公司第七届董事会董事长，选举李力先生为副董事长，任期自本次董事 会审议通过之日起三年。（简历见附件） 表决结果如下： 1、选举陈邦 ...

证券代码：300015 股票简称：爱尔眼科 公告编号：2025-098 爱尔眼科医院集团股份有限公司 关于董事会完成换届及聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 11 月 27 日召开 2025 年第三次临时股东大会，选举产生了第七届董事会非职工代表董事， 与公司 2025 年第一次职工代表大会选举产生的职工代表董事周建军先生共同组 成了公司第七届董事会。同日，公司召开第七届董事会第一次会议，审议通过了 选举公司第七届董事会董事长、副董事长、董事会各专门委员会委员及聘任高级 管理人员、董事会秘书、财务总监、证券事务代表的议案。现将有关情况公告如 下： 一、第七届董事会及董事会各专门委员会组成情况 （一）董事会成员 1、非独立董事：陈邦先生（董事长）、李力先生（副董事长）、吴士君先生 2、独立董事：高国垒先生、刘端女士、田素华先生 3、职工代表董事：周建军先生 公司第七届董事会由 7 名成员组成，任期自公司 2025 年第三次临时股东大 会审议通过之日起三年 ...

爱尔眼科医院集团股份有限公司（以下简称"公司"）第六届董事会任期即 将届满，为保证董事会的规范运作，根据《公司法》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件及 《公司章程》等有关规定，于 2025 年 11 月 24 日召开公司 2025 年第一次职工代 表大会，经民主选举，一致同意选举周建军先生（简历详见附件）为公司第七届 董事会职工代表董事，与公司股东大会选举产生的六名非职工代表董事共同组成 公司第七届董事会，其任期自本次职工代表大会决议通过之日起至第七届董事会 任期届满之日止。 证券代码：300015 证券简称：爱尔眼科 公告编号：2025-095 爱尔眼科医院集团股份有限公司 关于选举第七届董事会职工代表董事的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 附件：个人简历 周建军先生，1970 年 8 月出生，中国国籍，无境外永久居留权，入职爱尔 眼科已逾 20 年，曾任职于公司总裁办，现任公司行政人资部后勤主管，对公 司发展历程及员工权益状况具有全面和深入的了解。 截至本公告日，周建军先生持有本 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32] - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10] - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [17][18][22] Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32] - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32] Hidradenitis Suppurativa (HS) Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10] - The disease's complex pathogenesis involves multiple immune pathways, making it a target for various therapeutic approaches [11][27] Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in risks from policy changes [42][43] - It highlights the potential for growth in the CXO sector, particularly in CDMO and clinical CRO segments, as they continue to show strong performance despite market challenges [42][43] Recommended Stocks - The report lists several companies with strong growth potential, including Mindray Medical, WuXi AppTec, and Aier Eye Hospital, all rated as "Outperform" [4][44] - Mindray Medical is noted for its robust R&D and international expansion, while WuXi AppTec is recognized for its comprehensive drug development services [44]

Core Insights - Aier Eye Hospital has been awarded the "2024-2025 Most Respected Enterprise in New Quality Productivity" for its achievements in digital innovation and quality development [2] - The company operates 974 hospitals and eye centers globally, with 811 located in mainland China, demonstrating extensive coverage of quality eye care resources [2] - Aier Eye Hospital's innovative business model includes a tiered chain system that enhances medical resource allocation and accessibility, especially in underserved areas [3] Business Model Innovation - The tiered chain model consists of flagship hospitals in major cities, provincial hospitals, and county-level hospitals, optimizing the distribution of high-quality eye care services [3] - Aier has also introduced a "cross-subsidy" model to support low-income patients, enhancing the accessibility of eye care services [3] Research and Development - The company emphasizes innovation-driven strategies, establishing a comprehensive ecosystem for research, clinical application, and talent development [4] - Aier has strengthened partnerships with top universities to enhance its research capabilities and improve the quality of eye care [4] Quality and Safety Management - Aier Eye Hospital focuses on a systematic quality control framework and digital transformation to ensure patient safety and service quality [5] - The company aims to synchronize its medical technology and services with international standards, enhancing global patient access to innovative treatments [5] Digital Transformation - Since 2018, Aier has initiated a "Digital Ophthalmology" model, leveraging big data to improve service efficiency and quality [5] - The establishment of a health big data center and the development of smart hospital systems have been key components of this digital strategy [5] Artificial Intelligence Integration - Aier Eye Hospital has developed a comprehensive platform that integrates AI technologies into its service delivery, enhancing diagnostic and treatment processes [6] - The company aims to create a world-class eye medical center by leveraging new quality productivity and optimizing resource allocation [6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32]. - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10]. - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [2][18]. Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32]. - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32]. Hidradenitis Suppurativa Treatment Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10]. - First-line treatments primarily involve antibiotics, while second-line therapies include biologics such as Adalimumab and newer agents targeting IL-17A and IL-17A/F [2][10]. Company Earnings Forecast and Investment Ratings - Key companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform," with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][42]. - The report highlights the strong growth potential in the CXO sector, particularly in CDMO and clinical CRO services, driven by new orders and emerging business lines [42][43]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in various policy risks [42]. - It also emphasizes the importance of monitoring the clinical progress of innovative drugs in overseas markets, as this can significantly impact their commercialization potential [43][42]. Recommended Stocks - Mindray Medical is noted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure development [44]. - WuXi AppTec is recognized for its comprehensive service capabilities across the new drug development chain, poised to benefit from the global outsourcing market [44]. - Aier Eye Hospital is highlighted for its scale and commitment to introducing international standards in eye care [44].

"每一次为患者手术，都是一份信任的托付。突破400例，意味着我们肩上的责任更重一分。"刘云川表示，"真正 的精准医疗，不在于追求最高的手术量，而在于为每一双眼睛找到最理想的手术方案。我们的核心差异在于，始 终坚持以专家的深度思考驾驭前沿技术，将科技的确定性与我们经验的灵活性相结合，为患者铺就一条安心、清 晰的视觉之路。" 日前，国内屈光手术权威专家、济南爱尔眼科（300015）医院刘云川院长主导的新一代蔡司VISUMAX800机器人 全飞秒手术(SMILE pro)成功突破400例。 400例手术，是四百次精准的个性化定制。在刘云川看来，顶尖设备是基石，而专家的"精"与"验"才是实现卓越疗 效的核心。每一台SMILE pro手术的背后，都是她基于深厚理论功底与数十年近视手术临床经验所做的精准判 断：面对不同的角膜条件与用眼需求，刘云川团队在术前进行精细化数据解读，确保手术方案与每位患者的眼部 条件及生活品质追求完美契合。凭借对设备性能的极致理解与炉火纯青的操作，她将"10秒内完成切削"的技术参 数，升华为"稳、准、柔"的患者手术体验，帮助患者获得长期、稳定的视觉健康。 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (983036) closed at 4375.4 points on November 25, with a 0.52% increase and a trading volume of 8.459 billion HKD, indicating a positive market sentiment in the healthcare sector [1]. Group 1: Index Performance - The index had 40 stocks rising and 16 stocks falling on the day, with Ping An Good Doctor leading the gainers at a 4.27% increase, while Ruimaite led the decliners with a 1.98% drop [1]. - The index's turnover rate was 0.84%, reflecting moderate trading activity [1]. Group 2: Component Stocks Details - The top ten component stocks of the index include: - Mindray Medical (14.56% weight, 193.88 HKD, 0.46% increase, market cap 235.068 billion HKD) [1] - Yeye Eye Hospital (11.62% weight, 11.59 HKD, 0.35% increase, market cap 108.081 billion HKD) [1] - Lejin Medical (4.85% weight, 15.80 HKD, 0.45% increase, market cap 29.126 billion HKD) [1] - Aimeike (4.80% weight, 145.54 HKD, -0.31% decrease, market cap 44.039 billion HKD) [1] - Yuyue Medical (4.66% weight, 35.67 HKD, -0.14% decrease, market cap 35.758 billion HKD) [1] - Yingke Medical (3.64% weight, 40.26 HKD, 0.20% increase, market cap 26.362 billion HKD) [1] - Furuishi (3.59% weight, 65.75 HKD, -1.50% decrease, market cap 17.422 billion HKD) [1] - Meinian Health (3.58% weight, 5.42 HKD, 0.74% increase, market cap 21.215 billion HKD) [1] - Sinopharm (3.35% weight, 18.55 HKD, 0.49% increase, market cap 57.888 billion HKD) [1] - Ping An Good Doctor (2.63% weight, 13.33 HKD, 4.27% increase, market cap 28.822 billion HKD) [1]. Group 3: Capital Flow - The net outflow of main funds from the index's component stocks totaled 251 million HKD, while retail investors saw a net inflow of 199 million HKD [1]. - The detailed capital flow indicates that while main funds were withdrawing, retail investors were actively buying into the market [2]. Group 4: Recent Adjustments - In the last 10 days, the index underwent adjustments, adding one new stock, Jianfa Zhixin, which is in the medical biology sector with a market cap of 13.886 billion HKD [3].